Skip to main content
CertificationsCritical Care

How Do You Organize ICU Medications for CCRN Study?

When the medication list starts to feel like names to memorize, bring it back to a patient change you recognize. Build your CCRN study notes around what you’re trying to change. Is the problem vascular tone? Heart rate? Airflow? Then follow the drug from its target to the change you’d expect to see. You want to explain why the monitor changes, not only recognize the drug name.

S

Sachi, CRNA

CRNA

Last updated ·4 min read
CRNA Club study guide: How Do You Organize ICU Medications for CCRN Study?
In This Article (7 sections)

Use the pharmacology lessons and practice questions in the CCRN Toolkit to work through those connections. The paid toolkit and the seven-day platform trial are separate offers. The trial adds the wider clinical learning and interview tools.

What should you put on one medication page?

Let’s break it down with a drug you know from work. Answer four questions:

  1. Where does it act?
  2. What changes in that tissue?
  3. What will you look for in the patient?
  4. What finding would make you reassess?

Take phenylephrine. It mainly activates alpha-1 receptors in vascular smooth muscle. That muscle contracts, the vessels narrow and resistance rises. Arterial pressure tends to go up.

So why can the heart rate come down? The higher pressure triggers the baroreceptor response. The body slows the heart in response to the pressure change.

Now the bradycardia has a reason. You don’t have to memorize it as an unrelated fact at the bottom of the page. Try that explanation after the phenylephrine material in the CCRN Toolkit, then check which step you needed to look up.

Why isn’t knowing the receptor enough?

You also need to know which tissue you’re in. Beta-1 and beta-2 receptors both commonly use Gs, a relay protein inside the cell. That pathway raises cyclic AMP, which carries the signal onward.

But why would one pathway make the heart contract more strongly and the airway relax? Because the signal reaches different proteins in those tissues.

In the heart, beta-1 signaling supports a faster rate and stronger contraction. In bronchial smooth muscle, beta-2 signaling supports relaxation, opening the airway.

So “cyclic AMP goes up” doesn’t finish the explanation. Say what happens next in the tissue you’re discussing. That’s the part connecting the pathway to your patient.

How should you compare medications?

Compare what each drug reaches and what you’re trying to change:

Drug example Where to start What to explain next
Phenylephrine Mainly alpha-1 activation Increased vascular resistance, pressure and possible reflex slowing
Albuterol Beta-2 activation Relaxation of bronchial smooth muscle and the change in airflow
Dexmedetomidine Alpha-2 activation Less sympathetic signaling, sedation and hemodynamic effects
Milrinone PDE3 inhibition More cyclic AMP, stronger cardiac contraction and vasodilation

Milrinone is useful to compare because it gets to cyclic AMP differently. PDE3 is an enzyme that breaks cyclic AMP down. Blocking it lets more cyclic AMP remain. You still need to follow what that signal does in heart muscle and vascular smooth muscle.

Keep the DailyMed label database available for the actual formulation and approved indication. Your study page helps you reason through a question. At work, you still use the medication order and assess the individual patient.

How do you test whether you understand it?

Try this question: A patient’s pressure rises after phenylephrine while heart rate falls. Does that mean phenylephrine blocks beta-1 receptors?

No. Start with the alpha-1 effect on vascular tone. Then follow the rise in arterial pressure into the baroreflex. Two connected steps explain the two monitor changes.

What would you want to know next? Whether perfusion improved. Pressure also depends on resistance, so a higher number doesn’t tell you cardiac output by itself. Look at the clinical perfusion findings and other hemodynamic information you have.

What should you add after a missed question?

Add the connection you missed. If you confused pressure with flow, go back to that relationship and work through an example. You don’t need a second full drug sheet repeating everything you already wrote.

Then cover the chart and explain it again. Where do you stop? That’s the section to review before adding another medication.

Our Final Thoughts

You can build this one medication at a time. Start with a drug you know from work, cover the notes and explain why the patient changes. If you lose the connection at one step, that’s a useful place to return to before adding more names.

Build the next drug comparison

Work through a pharmacology lesson and related questions in the CCRN Toolkit, then compare the next drug with what you’ve learned. For the wider learning library and interview tools, try the platform for seven days.

Tags:CRNA schoolCCRN pharmacology study guide

Frequently Asked Questions

Do I need a separate page for every medication?

Start with a few drugs that help you understand each group. Give a drug its own page when it has a difference you need to work through. Recopying the same explanation under every name adds work without explaining more.

Should I memorize receptors before mechanisms?

Learn them together. Name the receptor, say which tissue it is in and follow what changes there. That helps you explain the patient effect instead of stopping at a label.

Where should I verify a drug fact?

Check current official labeling for the actual formulation and use an appropriate pharmacology reference. DailyMed provides labeling for many products.

Does a higher blood pressure prove better cardiac output?

No. Higher resistance can raise pressure without improving flow. Look at perfusion and the hemodynamic information available before deciding the patient is moving more blood.

How do I review a missed medication question?

Find the step you could not explain, review it and try again with the chart hidden. Use the lessons and questions in the CCRN Toolkit to practice that connection.